This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech     $Esperion Therapeutics (ESPR.US)$  Esper...

$Tilray Brands (TLRY.US)$ TLRY offers more upside reward than downside risk at current levels. TLRY is growing revenues & is trading well below it's book value of $3.97 a share, it has unfairly seen a decline in price while being fully lumped in with the cannabis sector.
TLRY is a lifestyle consumer products company that engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United St...

$Plug Power (PLUG.US)$ Oct. 29, 2024, 05:42 AM
In a report released today, Kashy Harrison from Piper Sandler maintained a Sell rating on Plug Power (PLUG – Research Report), with a price target of $1.60. The company’s shares closed yesterday at $2.24.

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

$Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics Non Statin Multi-Billion future Drug NEXLIZET has Reversed Type2 Diabetes After Removing Statin Drug to Lower Bad Cholesterol
$Esperion Therapeutics (ESPR.US)$
https://www.youtube.com/watch?v=DMW-BtT7WWE
From YouTube
Latest is Esperion has moved it's earnings date forward from scheduled 11/11 to 11/05. We know speculation is that Esperion might be selling some or all of the rights to it's Cholesterol d...

$Esperion Therapeutics (ESPR.US)$ The recent analyst note from Jeff sugest Esperion might sell the entire rights for Bempedoic Acid. Fair valuation on the rights would be above $1.5 billion, based on future milestones $900 million, future royalties & patents, the current formulation patent has exp date Dec 2031. The potential yearly sales in the U.S could reach $4 billion by 2027.
Esperion could also partner in the U.S .
Keep an...